Parsaclisib Leads to Clinically Meaningful Activity in R/R MCL Previously Treated with Ibrutinib

By DocWire News Editors - Last Updated: April 6, 2023

Parsaclisib was clinically active in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who were previously treated with ibrutinib, according to results of the CITADEL-205 trial presented at the 62nd American Society of Hematology Annual Meeting & Exposition.

Advertisement

Researchers of the study, led by Pier Luigi Zinzani, MD, from the University of Bologna in Italy, assessed the objective response rate (ORR) associated with parsaclisib in adult patients with R/R MCL. Patients in this study had received a median of three prior systemic therapies, including ibrutinib.

The investigators assigned patients to once-daily parsaclisib 20 mg for eight weeks followed by either once-weekly 20 mg or once-daily 2.5 mg. Additionally, the researchers initiated prophylaxis for pneumocystis jirovecii pneumonia.

A total of 47 patients were treated in the study, but 70% of patients discontinued at time of data cutoff. Treatment discontinuation was primary due to progressive disease (62%). The median treatment exposure was 2.2 months, and the median age was 70 years. Most patients were men (79%) and had an Eastern Cooperative Oncology Group performance status score of 1 or more (85%).

After the median follow-up period of 10.2 months, the ORR in 46 patients evaluable for efficacy was 28.3% (95% confidence interval [CI], 16.0-43.5), whereas the complete response rate was 2.2%. Additionally, the median duration of response was 7.3 months (95% CI, 0.2 to not estimable) in responders. Overall, the median time to a complete or partial response was 7.6 weeks.

Also, the investigators found that the median overall progression-free survival in this population was 3.65 months (95% CI, 1.9-3.9).

The most common treatment-emergent adverse events (AEs) in the 47 safety-evaluable patients were anemia (19.1%), diarrhea (19.1%), neutropenia (14.9%), asthenia (12.8%), cough (12.8%), decreased appetite (10.6%), dyspnea (10.6%), fatigue (10.6%), pyrexia and rash (10.6%).

Serious treatment-related AEs that occurred in two or more patients included diarrhea, dyspnea, peripheral swelling, and pneumonia (4.3% each).

Post Tags:ASH 2020 MCLMCL
Advertisement